Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Regenerative Medicine International (OTCPK:CNRMF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
China Regenerative Medicine International Receivables Turnover Related Terms
China Regenerative Medicine International Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Receivables Turnover Chart
China Regenerative Medicine International Annual Data
CNRMF vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Receivables Turnover vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International (CNRMF) has a Receivables Turnover of 14.81 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Regenerative Medicine International and its competitors. According to the industry distribution chart, China Regenerative Medicine International ranks #53 out of 841 companies in the Biotechnology industry, placing it in the top 6.3%.
Is China Regenerative Medicine International's Receivables Turnover too high?
China Regenerative Medicine International's current Receivables Turnover is 14.81. The Biotechnology industry median Receivables Turnover is 5.27. China Regenerative Medicine International's value of 14.81 is 181% above this industry median. Based on the distribution chart, China Regenerative Medicine International ranks #53 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #53 out of 841 companies for Receivables Turnover. This places China Regenerative Medicine International in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. China Regenerative Medicine International's value of 14.81 is 181% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Regenerative Medicine International's current Receivables Turnover of 14.81 is 181% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current Receivables Turnover is 14.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
China Regenerative Medicine International (CNRMF) has a current Receivables Turnover of 14.81. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 61.1% below its estimated fair value. The current Receivables Turnover is 14.81 and 181% above the Biotechnology industry median of 5.27. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For China Regenerative Medicine International (CNRMF), the current Receivables Turnover is 14.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.
Key valuation signals for CNRMF:
Receivables Turnover: 14.81
GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
Industry Position: 181% above the Biotechnology median (#53 of 841)
No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for CNRMF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNRMF has been successfully added to your 
